Actuate (ACTU) news
Recent news
Lutnick: Two years agreed to give manufacturers sufficient time to build up supply chain; no third year of relief
Lutnick: Two years agreed to give manufacturers sufficient time to build up supply chain; no third year of relief Landstar System, Inc. (NASDAQ: LSTR) has announced the rescheduling of its 2025 first quarter earnings release and conference call to May 13, 2025, from the previously planned date of…
AInvest Wire · Apr 29, 2025Actuate Therapeutics opens at $9.88, IPO at $8.
Actuate Therapeutics opens at $9.88, IPO at $8. Actuate Therapeutics (ACTU), a Phase 2 biotech specializing in the development of innovative therapies for difficult-to-treat cancers, recently adjusted the terms for its upcoming initial public offering (IPO) [1]. The company now plans to raise $27…
AInvest Wire · Aug 13, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.